Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

The Use of Low-Dose Alemtuzumab as Single Agent in the Treatment of Complication in Advanced Chronic Lymphocytic Leukaemia

Luca Laurenti, MD, Michela Tarnani, Idanna Innocenti, Silvia De Matteis, Simona Sica, Federica Sorà, Patrizia Chiusolo, Dimitar Efremov, MD, PhD, Sara Marietti, Giuseppe Leone

Blood (2008) 112 (11): 4212.

https://doi.org/10.1182/blood.V112.11.4212.4212

Published: 2008

Journal Articles

CD38 and ZAP-70 are functionally linked and mark CLL cells with high migratory potential

Silvia Deaglio, Tiziana Vaisitti, Semra Aydin, Luciana Bergui, Giovanni D'Arena, Lisa Bonello, Paola Omedé, Maria Scatolini, Ozren Jaksic, Giovanna Chiorino, Dimitar Efremov, Fabio Malavasi

Blood (2007) 110 (12): 4012–4021.

https://doi.org/10.1182/blood-2007-06-094029

Published: 2007

Journal Articles

Germline IgVH, del(17p13.1) and del(11q22.3) Predict Duration of Response in Patients Affected by Chronic Lymphocytic Leukaemia Treated with Oral Fludarabine and Cyclophosphamide as First-Line Therapy.

Luca Laurenti, MD, Dimitar Efremov, Md., Michela Tarnani, Md, Laura de Padua, Md, Nicola Piccirillo, Md, Patrizia Chiusolo, Md, Federica Sora’, Md, Simona Sica, Md, Gina Zini, Md, Mariagrazia Garzia, Md, Giuseppe Leone, Md

Blood (2007) 110 (11): 4717.

https://doi.org/10.1182/blood.V110.11.4717.4717

Published: 2007

Journal Articles

CD38 and ZAP-70 Mark Chronic Lymphocytic Leukemia (CLL) Cells with High Migratory Potential and Regulate Chemotaxis.

Silvia Deaglio, MD, PhD, Semra Aydin, M.D., Tiziana Vaisitti, Ph.D., Luciana Bergui, M.D., Giovanni D’Arena, M.D., Lisa Bonello, Ph.D, Paola Omedé, Ph.D., Giovanna Chiorino, Ph.D, Dimitar Efremov, M.D., Fabio Malavasi, M.D.

Blood (2007) 110 (11): 4684.

https://doi.org/10.1182/blood.V110.11.4684.4684

Published: 2007

Journal Articles

Low-Dose Alemtuzumab as Treatment for Pre-Treated CLL Patients. Evaluation of Response Rate, CMV Disease and Immune Recovery.

Luca Laurenti, Michela Tarnani, Paola Piccioni, Dimitar Efremov, Patrizia Chiusolo, Alessia Fiorini, Mariagrazia Garzia, Gina Zini, Mariangela Palladino, Silvia Bellesi, Carlo Rumi, Simona Sica, Giuseppe Leone

Blood (2004) 104 (11): 4823.

https://doi.org/10.1182/blood.V104.11.4823.4823

Published: 2004

NARROW

The Use of Low-Dose Alemtuzumab as Single Agent in the Treatment of Complication in Advanced Chronic Lymphocytic Leukaemia

CD38 and ZAP-70 are functionally linked and mark CLL cells with high migratory potential

Germline IgVH, del(17p13.1) and del(11q22.3) Predict Duration of Response in Patients Affected by Chronic Lymphocytic Leukaemia Treated with Oral Fludarabine and Cyclophosphamide as First-Line Therapy.

CD38 and ZAP-70 Mark Chronic Lymphocytic Leukemia (CLL) Cells with High Migratory Potential and Regulate Chemotaxis.

Low-Dose Alemtuzumab as Treatment for Pre-Treated CLL Patients. Evaluation of Response Rate, CMV Disease and Immune Recovery.

Email alerts

ASH Publications

American Society of Hematology

The Use of Low-Dose Alemtuzumab as Single Agent in the Treatment of Complication in Advanced Chronic Lymphocytic Leukaemia

CD38 and ZAP-70 are functionally linked and mark CLL cells with high migratory potential

Germline IgVH, del(17p13.1) and del(11q22.3) Predict Duration of Response in Patients Affected by Chronic Lymphocytic Leukaemia Treated with Oral Fludarabine and Cyclophosphamide as First-Line Therapy.

CD38 and ZAP-70 Mark Chronic Lymphocytic Leukemia (CLL) Cells with High Migratory Potential and Regulate Chemotaxis.

Low-Dose Alemtuzumab as Treatment for Pre-Treated CLL Patients. Evaluation of Response Rate, CMV Disease and Immune Recovery.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only